Form 4: Relay Therapeutics CFO Executes Stock Sale

Chief Financial Officer Thomas Catinazzo sold 17,717 shares of Relay Therapeutics common stock via a pre-arranged 10b5-1 trading plan.

Summary

• Thomas Catinazzo, CFO of Relay Therapeutics, sold 17,717 shares of common stock on May 14, 2026.
• The shares were sold at a weighted average price of $12.86 per share, with individual trade prices ranging from $12.67 to $13.42.
• Following the transaction, the reporting person retains beneficial ownership of 195,178 shares, which includes 9,807 shares underlying restricted stock units.
• The sale was conducted pursuant to a Rule 10b5-1 trading plan adopted on October 30, 2025.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the sale was pre-planned and represents a routine liquidity event for an executive.

Positives

• The transaction was executed under a pre-established Rule 10b5-1 trading plan, which is designed to avoid concerns regarding insider trading by scheduling sales in advance.

Negatives

• The sale represents a reduction in the direct equity stake held by a key member of the executive management team.

Risks

• Market volatility could impact the value of remaining holdings.
• Future sales by insiders may occur as part of ongoing 10b5-1 plans.

Future Outlook

No specific forward-looking guidance regarding company operations was provided in this filing.

Industry Context

StockSavvy.ai notes that executive stock sales under 10b5-1 plans are standard corporate practice and generally do not signal a change in company fundamentals or management sentiment regarding the firm's long-term prospects.

Comparison to Industry Standards

• The use of Rule 10b5-1 plans is the industry standard for executives to liquidate equity positions while maintaining regulatory compliance.

Stakeholder Impact

• Minimal impact expected as the sale was conducted via a pre-arranged plan.

Next Steps

• Continued monitoring of future Form 4 filings for additional insider activity.

Key Dates

Keywords

Relay Therapeutics, RLAY, Insider Trading, Form 4, CFO, Stock Sale